Background: To determine whether the alleles that influence type 2 diabetes risk and glycemic traits also influence prostate cancer risk.
Methods: We used a multiple single nucleotide polymorphisms (SNP) genotypic risk score to assess the average effect of alleles that increase type 2 diabetes risk or worsen glycemic traits on risk of prostate cancer in 19,662 prostate cancer cases and 19,715 controls from the PRACTICAL consortium and 5,504 prostate cancer cases and 5,834 controls from the CRUK prostate cancer study.
Results: Calculating the average additive effect of type 2 diabetes or glycemic trait risk alleles on prostate cancer risk using a logistic model revealed no evidence of a shared allelic architecture between type 2 diabetes, or worsened glycemic status, with prostate cancer risk (odds ratio for type 2 diabetes alleles: 1.00 (P=0.58), fasting glycemia alleles: 1.00 (P=0.67), HbA1c alleles: 1.00 (P=0.93), 2 hour OGTT alleles: 1.01 (P=0.14) and HOMA-B alleles: 0.99 (P=0.57)).
Conclusions: Using genetic data from large consortia we found no evidence for a shared genetic etiology of type 2 diabetes, or glycemic risk, with prostate cancer. Impact:Our results showed that alleles influencing type 2 diabetes and related glycemic traits were not found to be associated with the risk of prostate cancer.
Written by:
Yu OH, Foulkes WD, Dastani Z, Martin RM, Eeles R, Richards JB. Are you the author?
McGill University, Canada.
Reference: Cancer Epidemiol Biomarkers Prev. 2013 May 23. Epub ahead of print.
doi: 10.1158/1055-9965.EPI-13-0476
PubMed Abstract
PMID: 23704474
